First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer – Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110)

Autor: Stahler, Arndt, Modest, Dominik P., Fischer von Weikersthal, Ludwig, Kaiser, Florian, Decker, Thomas, Held, Swantje, Graeven, Ullrich, Schwaner, Ingo, Denzlinger, Claudio, Schenk, Michael, Kurreck, Annika, Heinrich, Kathrin, Gießen-Jung, Clemens, Neumann, Jens, Kirchner, Thomas, Jung, Andreas, Stintzing, Sebastian, Heinemann, Volker
Zdroj: In European Journal of Cancer September 2022 173:194-203
Databáze: ScienceDirect
Externí odkaz: